Barclays analyst Andrew Mok lowered the firm’s price target on Humana (HUM) to $268 from $273 and keeps an Equal Weight rating on the shares as part of an investor day preview. The firm expects the company to outline embedded earnings and the path to 3% Medicare Advantage margins, but does not anticipate any formal earnings targets or 2026 guidance.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUM:
- Trump Trade: Tesla bouncing back after $152B in market cap loss amid Musk spat
- Senate Republicans consider Medicare spending cuts, Bloomberg says
- UnitedHealth, Humana, CVS fall after Bloomberg report on possible Medicate cuts
- Humana to support moves to curb Medicare billing practices, WSJ says
- Trump Trade: Trump says Fed ‘must now’ lower rates after jobs report